FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth

Kayed, Hany; Kleeff, Jörg; Kolb, Armin; Ketterer, Knut; Keleg, Shereen; Felix, Klaus; Giese, Thomas; Penzel, Roland; Zentgraf, Hanswalter; Büchler, Markus W.; Korc, Murray; Friess, Helmut

doi:10.1002/ijc.21257

Cited by 62 publications

(74 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Keratin has been confirmed to be associated with colorectal carcinoma. Fibulin-like extracellular matrix protein 1 (fibulin1) and Fxyd3 protein have been confirmed as overexpressed in gastric adenocarcinoma, colorectal cancer, pancreatic cancer, and other tissue cancers [20,21]. A number of apoptosis-and cancer-related genes showed increased expressions in the liver of rats, indicating that the Dendrobium mixture helped to maintain normal cell differentiation and apoptosis.…”

Section: Discussionmentioning

confidence: 99%

Gene Expression and Microarray Investigation of Dendrobium Mixture as Progressive Therapy for the Treatment of Type 2 Diabetes Mellitus

Xu¹,

Liu²,

Yu³

et al. 2013

Trop. J. Pharm Res

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Gene Expression and Microarray Investigation of Dendrobium Mixture as Progressive Therapy for the Treatment of Type 2 Diabetes Mellitus

Xu¹,

Liu²,

Yu³

et al. 2013

Trop. J. Pharm Res

View full text Add to dashboard Cite

“…The data suggest that the peaks in the PISEMA spectrum will have to be fitted with Pisa wheels of different tilts, in agreement with the solution NMR studies in micelles, showing that helices 1 and 2 have different orientations. According to the data in micelles, the peaks in the spectrum of 15 N-Leu labeled CHIF should account for Leu 17 and 19 in helix 1 preceding the transmembrane helix (helix 2), and Leu 22,27,28,35,37 in the transmembrane helix.…”

Section: 34mentioning

confidence: 99%

“…FXYD2 (gamma) and FXYD4 (CHIF; channel-inducing factor; corticosteroid hormone induced factor), are each expressed in distinct, specialized segments of the kidney, with unique expression patterns that help explain the physiological differences in Na,K-ATPase activity among the nephron segments [21][22][23][24][25]. FXYD3 (Mat8; mammary tumor protein 8 kDa) is expressed in cancers and plays a role in tumor progression [26,27]. Despite their relatively small sizes ranging from about 60-160 amino acids, all FXYD proteins are encoded by genes with six to nine small exons, and NMR has shown that the protein structures reflect the structures of their corresponding genes, suggesting that they were assembled from modules through exon shuffling [28].…”

Section: Introductionmentioning

confidence: 99%

NMR of membrane proteins in micelles and bilayers: The FXYD family proteins

Franzin

Gong

Thai

et al. 2007

Methods

View full text Add to dashboard Cite

Determining the atomic resolution structures of membrane proteins is of particular interest in contemporary structural biology. Helical membrane proteins constitute one-third of the expressed proteins encoded in a genome, many drugs have membrane-bound proteins as their receptors, and mutations in membrane proteins result in human diseases. Although integral membrane proteins provide daunting technical challenges for all methods of protein structure determination, nuclear magnetic resonance (NMR) spectroscopy can be an extremely versatile and powerful method for determining their structures and characterizing their dynamics, in lipid environments that closely mimic the cell membranes. Once milligram amounts of isotopically labeled protein are expressed and purified, micelle samples can be prepared for solution NMR analysis, and lipid bilayer samples can be prepared for solid-state NMR analysis. The two approaches are complementary and can provide detailed structural and dynamic information. This paper describes the steps for membrane protein structure determination using solution and solid-state NMR. The methods for protein expression and purification, sample preparation and NMR experiments are described and illustrated with examples from the FXYD proteins, a family of regulatory subunits of the Na, KATPase.

show abstract

“…FXYD-3 is a trans-membrane protein normally present in body tissues but overexpressed in several cancers. Increased expression in early tumour differentiation and tumour proliferation has indicated that it could possibly be used as a tumour marker (19,(71)(72)(73)(74)(75). There are also indications that FXYD-3 may be involved in tumour resistance to 5-FU chemotherapy (76).…”

Section: Study Imentioning

confidence: 99%

Response to neoadjuvant treatment in rectal cancer surgery

Loftås

2016

Linköping University Medical Dissertations

View full text Add to dashboard Cite

Rectal cancer is one of the three most common malignancies in Sweden with an annual incidence of about 2000 cases. Current treatment consists of surgical resection of the rectum including the loco-regional lymph nodes in the mesorectum. In advanced cases, neoadjuvant chemo-radiotherapy (CRT) prior to the operative treatment reduces local recurrences and enables surgery. The neoadjuvant treatment can also eradicate the tumour completely, i.e. complete response. This research project was designed to investigate the effects of preoperative radiotherapy/ CRT and analyze methods to predict response to CRT. Study I investigated the expression of the FXYD-3 protein with immunohistochemistry in rectal cancer, with or without preoperative radiotherapy. The results from the total cohort showed that, strong FXYD-3 expression was correlated to infiltrative tumour growth (p = 0.02). In the radiotherapy group, strong FXYD-3 expression was related to an unfavourable prognosis (p = 0.02). Tumours with strong FXYD-3 expression had less tumour necrosis (p = 0.02) after radiotherapy. FXYD-3 expression in the primary tumour was increased compared to normal mucosa (p=0.008). We concluded that FXYD-3 expression was a prognostic factor in patients receiving preoperative radiotherapy for rectal cancer. Study II investigated FXYD-3 expression in tumours that developed local recurrences following surgery and compared this with expression in tumours that did not develop local recurrences. There was no difference in the expression of FXYD-3 between the group that developed local recurrences and the group that did not develop local recurrences. There was no difference in survival between those with strong or weak FXYD-3 expression. We concluded that this study could not confirm the findings from study 1 i.e. that FXYD-3 expression has prognostic significance in rectal cancer. Study III was a register-based study on the incidence and effects of complete response to neoadjuvant treatment. Eight per cent of the patients with adequate CRT to achieve complete response also had a complete histological response of the luminal tumor in the resected bowel. Sixteen per cent of that group had remaining lymph node metastases in the operative specimen. Chemotherapy together with radiotherapy doubled the chance of complete response in the luminal tumour. Patients with remaining lymph node metastases had a lower survival rate compared to those without. We concluded that residual nodal involvement after neoadjuvant treatment was an important factor for reduced survival after complete response in the luminal tumour. Study IV followed up the results from the previous study by re-evaluating magnetic resonance imaging (MRI)- images in patients with complete tumour response. Two experienced MRI radiologists performed blinded re-staging of post CRT MR- images from patients with complete response in the luminal tumour. One group with lymph node metastases and another one without were studied and the results compared with the pathology reports. The sensitivity, spe...

show abstract

FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth

Cited by 62 publications

References 24 publications

Gene Expression and Microarray Investigation of Dendrobium Mixture as Progressive Therapy for the Treatment of Type 2 Diabetes Mellitus

Gene Expression and Microarray Investigation of Dendrobium Mixture as Progressive Therapy for the Treatment of Type 2 Diabetes Mellitus

NMR of membrane proteins in micelles and bilayers: The FXYD family proteins

Response to neoadjuvant treatment in rectal cancer surgery

Contact Info

Product

Resources

About